Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio

oncodaily - Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics, marking a strategic expansion into rare disease treatments and strengthening its late-stage pipeline. The deal signals continued consolidation […]

AI Summary: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, picking up Soleno’s Prader‑Willi treatment candidate and bolstering its rare‑disease portfolio. The purchase folds Soleno’s clinical assets and research teams into Neurocrine, positioning the buyer to commercialize a potential high‑value therapy while shoring up long‑term pipeline growth.

Can a single therapy session make a difference? Yes, with the right mindset

abcnews - Can a single therapy session make a difference

AI Summary: Experts report that a single, well‑structured therapy session can produce meaningful short‑term benefits for some patients when expectations, mindset, and therapeutic focus align. It’s not a miracle cure, but the finding nudges clinicians and policymakers toward pragmatic, low‑burden interventions that can provide rapid relief while longer‑term care is arranged.